Testing atezolizumab with radiation and surgery for lung-only osteosarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether combining an immunotherapy drug (atezolizumab) with focused radiation and surgery can help people whose osteosarcoma has come back only in the lungs. It aims to see if this approach is safe and may improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must have osteosarcoma that has come back, with tumors only in the lungs.
- Doctors must be able to remove all lung nodules with surgery.
- You must have at least one nodule that can be treated with radiation and another nodule that needs surgery.
- Any side effects from past treatments must be mostly gone or stable.
- Your heart, lungs, kidney, liver, and blood counts must be healthy enough for this treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy and targeted radiation before surgery for osteosarcoma that has spread to the lungs. It aims to see if this approach can help shrink or control the lung tumors and make surgery more effective.
This trial tests a single, high-dose internal radiation treatment (brachytherapy) for large osteosarcoma tumors that can't be removed by surgery and haven't responded to other treatments. It may offer a new option for shrinking these difficult-to-treat masses.
This early-phase study tests whether adding losartan to sunitinib can help control osteosarcoma that has returned or keeps growing after at least one prior treatment. It may help by targeting the cancer’s growth signals and blood supply, but the goal at this stage is mainly to check safety and find workable dosing.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This trial tests a new drug called tegavivint combined with the chemotherapy drug gemcitabine for people whose osteosarcoma has come back or stopped responding to treatment. The goal is to see if this combination can help shrink or control the cancer.
This Phase 2 trial tests a highly focused radiation treatment to shrink sarcoma that has spread to a limited number of spots in the body. It may help control disease while limiting radiation to healthier tissue.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.